hydroxychloroquine for COVID-19 - live meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	RCT OBS RCT + OBS	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 hospitalized meta-analysis
Abd-Elsalam, 2020 NCT04353336		RCT	hydroxychloroquine	standard of care	COVID 19 hospitalized	some concern	97/97	inconclusive
ARCHAIC -hydroxychloroquine, 2020 NL8490		RCT	hydroxychloroquine	standard of care	COVID 19 hospitalized	NA	9/6	inconclusive
CCAP-1, 2020 NCT04345289		RCT	hydroxychloroquine	standard of care	COVID 19 hospitalized	NA	-/-	inconclusive
Chen, 2020 NCT04384380		RCT	hydroxychloroquine	standard of care	COVID 19 hospitalized	some concern	21/12	inconclusive
Duke university HCQ, 2020 NCT04335552		RCT	hydroxychloroquine	standard of care	COVID 19 hospitalized	NA	4/2	no results	discontinued, found in Axfors et al. meta-analysis
HYCOVID, 2020 NCT04325893		RCT	hydroxychloroquine	placebo	COVID 19 hospitalized	some concern	124/123	inconclusive	inconclusive 12 % increase in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
NO COVID-19 (Lyngbakken), 2020 NCT04316377		RCT	hydroxychloroquine	standard of care	COVID 19 hospitalized	some concern	27/26	inconclusive
OAHU-COVID19, 2020 NCT04345692		RCT	hydroxychloroquine	standard of care	COVID 19 hospitalized	NA	10/6	inconclusive
ORCHID, 2020 NCT04332991		RCT	hydroxychloroquine	placebo	COVID 19 hospitalized	low	242/237	inconclusive	inconclusive 2 % increase in clinical improvement (PE) with a high degree of certainty due to low risk of bias
RECOVERY, 2020 NCT04381936		RCT	hydroxychloroquine	standard of care	COVID 19 hospitalized	some concern	1561/3155	safety concern	inconclusive 9 % increase in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias statistically significant 14 % increase in death or ventilation with a moderate degree of certainty due to some concern in risk of bias
SOLIDARITY (WHO study) HCQ, 2020 NCT04315948		RCT	hydroxychloroquine	standard of care	COVID 19 hospitalized	some concern	947/906	inconclusive	inconclusive 19 % increase in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
Tang, 2020 ChiCTR2000029868		RCT	hydroxychloroquine	standard of care	COVID 19 hospitalized	high	75/75	safety concern	statistically significant 3.5-fold increase in adverse events but with a low degree of certainty due to high risk of bias
TEACH, 2020 NCT04369742		RCT	hydroxychloroquine	placebo	COVID 19 hospitalized	some concern	67/61	inconclusive	inconclusive 80 % increase in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias inconclusive 16 % increase in adverse events (PE) with a moderate degree of certainty due to some concern in risk of bias
Arshad (HCQ), 2020		OBS	hydroxychloroquine	control	COVID 19 hospitalized	critical	1202/409	suggested	suggested 66 % decrease in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias
Belgian Collaborative Group on COVID-19, 2020		OBS	hydroxychloroquine	control	COVID 19 hospitalized	serious	4542/3533	suggested	suggested 32 % decrease in deaths,deaths (time to event analysis only) but with a low degree of certainty due to high risk of bias
Geleris, 2020		OBS	hydroxychloroquine	control	COVID 19 hospitalized	serious	811/565	inconclusive
Magagnoli (HC), 2020		OBS	hydroxychloroquine	control	COVID 19 hospitalized	serious	97/158	safety concern	safety concern with statistically significant 1.6-fold increase in deaths,deaths (time to event analysis only)
Novales, 2020		OBS	hydroxychloroquine	control	COVID 19 hospitalized	critical	123/43	suggested	suggested 93 % decrease in deaths but with a very low degree of certainty due to critical risk of bias
Paccoud, 2020		OBS	hydroxychloroquine	standard of care	COVID 19 hospitalized	serious	38/46	inconclusive
Sbidian (HCQ alone), 2020		OBS	hydroxychloroquine	control	COVID 19 hospitalized	critical	623/3792	safety concern	statistically significant 25 % increase in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias
Singh, 2020		OBS	hydroxychloroquine	control	COVID 19 hospitalized	critical	-/-	inconclusive
COVID 19 all comers meta-analysis
ChiCTR2000030054-HCQ (Chen), 2020 ChiCTR2000030054		RCT	hydroxychloroquine	standard of care	COVID 19 all comers	high	18/12	inconclusive
Gautret et al., 2020		NRa	hydroxychloroquine	control	COVID 19 all comers	serious	20/16	suggested	suggested 15.3-fold increase in PCR-negative conversion (PE) but with a low degree of certainty due to high risk of bias a viral load reduction/disappearance is claimed but the numerous methological limits preclude any strong conclusion
COVID-19 mild to moderate meta-analysis
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 NCT04322123		RCT	hydroxychloroquine	standard of care	COVID-19 mild to moderate	some concern	221/227	safety concern	statistically significant 74 % increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
HC-nCoV (Shanghai), 2020 NCT04261517		RCT	hydroxychloroquine	standard of care	COVID-19 mild to moderate	some concern	15/15	inconclusive
NCT04333654, 2020 NCT04333654		RCT	hydroxychloroquine	standard of care	COVID-19 mild to moderate	NA	-/-	inconclusive
Zhaowei Chen, 2020 ChiCTR2000029559		RCT	hydroxychloroquine	control	COVID-19 mild to moderate	high	31/31	inconclusive
Zhaowei Chen, 2020 ChiCTR2000029559		RCT	hydroxychloroquine	standard of care	COVID-19 mild to moderate	high	31/31	suggested	suggested 2.4-fold increase in clinical improvement but with a low degree of certainty due to high risk of bias suggested 2.4-fold increase in radiologic improvement (7-day) but with a low degree of certainty due to high risk of bias
Min, 2020		OBS	hydroxychloroquine	control	COVID-19 mild to moderate	NA	20/20	inconclusive
COVID-19 severe or critically meta-analysis
HYDRA, 2020 NCT04315896		RCT	hydroxychloroquine	placebo	COVID-19 severe or critically	NA	75/77	inconclusive	inconclusive 1 % decrease in deaths (PE)
REMAP-CAP-HCQ, 2020 NCT02735707		RCT	hydroxychloroquine	standard of care	COVID-19 severe or critically	NA	61/81	inconclusive	inconclusive 4 % increase in deaths (PE) REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.multi-arm study
Mahevas, 2020		OBS	hydroxychloroquine	standard of care	COVID-19 severe or critically	serious	84/97	inconclusive
Yu, 2020		OBS	hydroxychloroquine	control	COVID-19 severe or critically	critical	48/520	suggested	suggested 68 % decrease in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 hospitalized meta-analysis

COVID 19 all comers meta-analysis

COVID-19 mild to moderate meta-analysis

COVID-19 severe or critically meta-analysis